Every Monday we share a quick “best of” from the week that was with our Inner Circle members. What’s trending in the Femtech Insider community and beyond? We’ve got you covered! In this week’s brief we talk about…
Highlights: All Eyes on Ovarian Biology, Maternal Health on the Rise & Reinventing the Dental Dam
Why are we excited about this field? Celmatix, Oviva and others are developing therapeutics, with the potential to postpone menopause, address infertility and solve for chronic conditions such as PCOS or endometriosis by leveraging ovarian biology in different ways. So their success could truly be a gamechanger for women’s health.
A few weeks ago we talked about “Maternal Health Mega Week” in this brief, when Delfina, Zaya, Noula & Wildflower Health all came out with funding announcements within less than a week. And the good news is: It wasn’t just a “lucky streak”.
Maternal health companies continue to attract fundingto bring much needed innovation to the space. Last week’s highlights included Cayaba Care raising a $12M Series A, Mahmee adding $9.2M in Series A funding, Pulsenmore inking a partnership with GE Healthcare (incl. up to $50M in funding) and biotech company Mirvie adding $60M for its RNA platform focused on early prediction of pregnancy complications.
➡️ Ever heard of a dental dam?
Well. You have now! Last week sexual wellness company Lorals made the news after receiving FDA clearance for STI protection for its latex briefs, that are to replace the outdated dental dam during oral intercourse. We spoke to founder Melanie Cristol back in January 2021, when she was just starting her “FDA journey” and are thrilled we got to share this milestone last week.
And what’s almost as exciting as the FDA clearance itself: The Lorals story made it into The New York Times! Huge win for destigmatization in our humble opinion!
➡️ In other news…
You’ve found some of our exclusive Inner Circle Content.
This article is only available for our Inner Circle Members. To read on:
